Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...

Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.75%, and the Nasdaq 100 Index ($IUXX) ...

FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide ...

Healthcare sector shows strong performance in January amid signs of a brighter 2025, according to analysts. Read more here.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The United States wants Ukraine to hold elections, potentially by the end of the year, especially if Kyiv can agree a truce ...

Brad Smith explores the topics most important to your wallet on Wealth. Compass realtor Melanie Atkinson discusses the ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts ...

Wall Street stocks closed lower on Friday despite a slightly better-than-expected US consumption reading. At the close, the Dow Jones Industrial Average was down 0.75% at 44,544.66, while the S&P 500 ...